1 – 7 of 7
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum
(
- Contribution to journal › Article
- 2005
-
Mark
Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-receptor and Biomarker Group collaboration
(
- Contribution to journal › Article
- 2004
-
Mark
Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study
(
- Contribution to journal › Article
- 2003
-
Mark
Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients
(
- Contribution to journal › Article
- 2002
-
Mark
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay
(
- Contribution to journal › Article
-
Mark
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer
(
- Contribution to journal › Article
-
Mark
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
(
- Contribution to journal › Article